Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BR3003 (Dapagliflozin/Pioglitazone) vs Components in Healthy Volunteers
NCT05411965Phase 1Completed
- Sponsor
- Boryung
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve and Maximum Plasma Concentration. Started Apr 2022; status: completed.
02
Drugs
dapagliflozinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05411965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411965.